Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody.
CONCLUSION: The c2A8 mAb is potentially a valuable tool for targeted immunotherapy of HER2 positive cancers.
PMID: 30864553 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Immunotherapy | Iran Health | Middle East Health